Cover Image

CAR-T Cell Therapy: Advances in Kidney-Related Diseases

Background: Chimeric antigen receptor (CAR)-T cell therapy represents a significant advancement in the field of immunotherapy, providing targeted eradication of abnormal cells through the recognition between CAR and target antigens. This approach has garnered considerable attention due to its promis...

Full description

Saved in:

Bibliographic Details
Main Authors:	Longyuan Wu (Author), Youqin Feng (Author), Yue Huang (Author), Jingjing Feng (Author), Yongxian Hu (Author), He Huang (Author)
Format:	Book
Published:	Karger Publishers, 2024-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CAR T Cell Therapy: Remedies of Current Challenges in Design, Injection, Infiltration and Working
by: Zhu Y, et al.
Published: (2023)

Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
by: Yadan Liu, et al.
Published: (2021)

The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions
by: Yanping Li, et al.
Published: (2022)

Donor T cells for CAR T cell therapy
by: Tiffany C. Y. Tang, et al.
Published: (2022)

Biomarkers as targets for CAR-T/NK cell therapy in AML
by: Ruonan Shao, et al.
Published: (2023)

Advances in CAR-T therapy for central nervous system tumors
by: Delian Zhou, et al.
Published: (2024)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
by: Zhenguang Wang, et al.
Published: (2018)

Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: Application to CAR-T cells
by: María Tristán-Manzano, et al.
Published: (2023)

Seatbelts in CAR therapy: How Safe Are CARS?
by: Kentaro Minagawa, et al.
Published: (2015)

Updates on CAR T cell therapy in multiple myeloma
by: Fatemeh Nasiri, et al.
Published: (2024)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
by: Zijun Zhao, et al.
Published: (2018)

CAR-based cell therapy: evaluation with bibliometrics and patent analysis
by: Yajun Yuan, et al.
Published: (2021)

Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy
by: Dian Xiong, et al.
Published: (2024)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
by: Laura Castelletti, et al.
Published: (2021)

Post-CAR-T cell therapy presenting as proteinaceous lymphadenopathy
by: Mishi Bhushan, et al.
Published: (2021)

CAR-NK cells for cancer immunotherapy: from bench to bedside
by: Leisheng Zhang, et al.
Published: (2022)

Strategies to enhance CAR-T persistence
by: Yue Liu, et al.
Published: (2022)

Research advances of arrhythmia in patients with chronic kidney disease
by: Zhong-xin Jin, et al.
Published: (2023)

Identification of cancer-specific cell surface targets for CAR-T cell therapy
by: Naoki Hosen
Published: (2024)

CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy
by: Behrouz Shademan, et al.
Published: (2022)

Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
by: Anna M. Mc Laughlin, et al.
Published: (2023)

Engineering CAR-T cells
by: Cheng Zhang, et al.
Published: (2017)

Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy
by: Si-Heng Zhang, et al.
Published: (2024)

Single-cell analysis of the survival mechanisms of fratricidal CAR-T targeting of T cell malignancies
by: Hui Hu, et al.
Published: (2024)

Building safety into CAR-T therapy
by: Daniel T. Peters, et al.
Published: (2023)

Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma
by: Shuto Negishi, et al.
Published: (2024)

A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023
by: Huimin Li, et al.
Published: (2023)

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
by: Johannes Kast, et al.
Published: (2022)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma
by: Maria Giraudo, et al.
Published: (2024)

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
by: Tadesse Asmamaw Dejenie, et al.
Published: (2022)

Emerging CAR T cell therapies: clinical landscape and patent technological routes
by: Virgínia Picanco-Castro, et al.
Published: (2020)

Effects of CAR-T Cell Therapy on Immune Cells and Related Toxic Side Effect Analysis in Patients with Refractory Acute Lymphoblastic Leukemia
by: Lianlian Li, et al.
Published: (2023)

Immunogenicity in CAR T cell immunotherapy
by: Emily Yu
Published: (2023)

Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects
by: Yuankui Zhu, et al.
Published: (2024)

CAR-T Cell Therapies for Non-Hematopoietic Malignancies: Taking Off The Training Wheels
Published: (2020)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
by: Hamed Dabiri, et al.
Published: (2023)

Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective
by: Xingxing Qi, et al.
Published: (2023)

Research advances in the outcomes of pregnancy-related acute kidney injury
by: Naiwubaier Abudukeyoumu, et al.
Published: (2024)

Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials
by: Xinrong Xiang, et al.
Published: (2020)

Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
by: Javad Masoumi, et al.
Published: (2021)